Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances

Submitted: 13 August 2020
Accepted: 7 December 2020
Published: 20 January 2021
Abstract Views: 1229
PDF: 509
Supplementary: 91
HTML: 10
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

As the leading malignancy among women, breast cancer is a serious threat to the life and health of women. In this context, it is of particular importance that a proper therapeutic target be identified for breast cancer treatment. We collected the pathological tissues of 80 patients, with the view to discovering appropriate molecular targets for the treatment of breast cancer, this paper analyzes the expressions of ZNF436, β-catenin, EGFR and CMTM5 in breast cancer tissues, as well as their correlations with breast cancer in combination with the clinicopathologic characteristics of studied patients. Immunohistochemistry (IHC) was utilized to detect the expression levels of ZNF436, β-catenin, EGFR and CMTM5 in cancerous and paracancerous tissues of breast cancer patients. The expression levels of ZNF436, β-Catenin and EGFR in breast cancer tissues were significantly greater than those in paracancerous tissues in this study (p<0.05), while CMTM5 was highly expressed in paracancerous tissues (p<0.05). Additionally, the correlation of the expressions of such indicators with the staging, differentiation and lymphatic metastasis of breast cancer, were also found to be statistically significant at the level p<0.05. The different expression levels of ZNF436, β-catenin, EGFR and CMTM5 in breast cancer and paracancerous tissues open up the possibility of utilizing them as molecular markers for breast cancer. These findings provide a theoretical basis for targeted molecular therapies for breast cancer, and hence carry a significant practical significance.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg 2017;69:313-7. DOI: https://doi.org/10.1007/s13304-017-0424-1
Bernhard W. Breast cancer: basics, screening, diagnostics, and treatment. Med Monatsschr Pharm 2017;40:55-64.
Fahad Ullah M. Breast cancer: Current perspectives on the disease status. Adv Exp Med Biol 2019;1152:51-64. DOI: https://doi.org/10.1007/978-3-030-20301-6_4
Shang Y, Li Y, Zhang Y, Wang J. ZNF436 promotes tumor cell proliferation through transcriptional activation of BCL10 in glioma. Biochem Biophys Res Commun 2019;515:572-8. DOI: https://doi.org/10.1016/j.bbrc.2019.06.004
Alamoud KA, Kukuruzinska MA. Emerging insights into Wnt/β-catenin signaling in head and neck cancer. J Dent Res 2018;97:665-73. DOI: https://doi.org/10.1177/0022034518771923
Shang S, Hua F, Hu ZW. The regulation of β -catenin activity and function in cancer: therapeutic opportunities. Oncotarget 2017;8:33972-89. DOI: https://doi.org/10.18632/oncotarget.15687
Yang F, Fang E, Mei H, Chen Y, Li H, Li D, et al. Cis-acting circ-CTNNB1 promotes β-catenin signaling and cancer progression via DDX3-mediated transactivation of YY1. Cancer Res 2019;79:557-1. DOI: https://doi.org/10.1158/0008-5472.CAN-18-1559
Wang Z. ErbB receptors and cancer. Methods Mol Biol 2017;1652:3-35. DOI: https://doi.org/10.1007/978-1-4939-7219-7_1
Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012;13:e23-e31. Erratum in Lancet Oncol 2011;12:1182.
Cai B, Xiao Y, Li Y, Zheng S. CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis. Oncol Lett 2017;14:1536-42. DOI: https://doi.org/10.3892/ol.2017.6350
Yuan YQ, Zhang YX, Liu ZH, Qin CP, Sheng ZZ, Xu T, et al. [Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].[Article in Chinese]. Beijing Da Xue Xue Bao Yi Xue Ban 2015;47:571-6.
Xiao Y, Yuan Y, Zhang Y, Li J, Liu Z, Zhang X, et al. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo. Clin Transl Oncol 2015;17:431-7. DOI: https://doi.org/10.1007/s12094-014-1253-z
Guo X, Li T, Wang Y, Shao L, Zhang Y, Ma D, et al. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha. Biochem Biophys Res Commun 2009;387:139-42. DOI: https://doi.org/10.1016/j.bbrc.2009.06.148
Wu J. CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma. Cancer Biomark 2020;29:89-99. DOI: https://doi.org/10.3233/CBM-191226
Zhou J, Lei J, Wang J, Lian CL, Hua L, He ZY, et al. Bioinformatics-based discovery of CKLF-like MARVEL transmembrane member 5 as a novel biomarker for breast cancer. Front Cell Dev Biol 2020;7:361. DOI: https://doi.org/10.3389/fcell.2019.00361
Varma K, Chauhan A, Bhargava M, Misra V, Srivastava S. Association of different patterns of expression of beta-catenin and cyclin D1 with pathogenesis of breast carcinoma. Indian J Pathol Microbiol 2020;63:13-8. DOI: https://doi.org/10.4103/IJPM.IJPM_419_19
Song X, Liu Z, Yu Z. EGFR promotes the development of triple negative breast cancer through JAK/STAT3 Signaling. Cancer Manag Res 2020;12:703-17. DOI: https://doi.org/10.2147/CMAR.S225376
Hong W, Dong E. The past, present and future of breast cancer research in China. Cancer Lett 2014;351:1-5. DOI: https://doi.org/10.1016/j.canlet.2014.04.007
Odle TG. Precision medicine in breast cancer. Radiol Technol 2017;88:401M-21.
Liu Y, Huang W, Gao X, Kuang F. Regulation between two alternative splicing isoforms ZNF148FL and ZNF148ΔN, and their roles in the apoptosis and invasion of colorectal cancer. Pathol Res Pract 2019;215:272-7. DOI: https://doi.org/10.1016/j.prp.2018.10.036
Gualtero DF, Suarez Castillo A. Biomarkers in saliva for the detection of oral squamous cell carcinoma and their potential use for early diagnosis: a systematic review. Acta Odontol Scand 2016;74:170-7. DOI: https://doi.org/10.3109/00016357.2015.1110249
O'Reilly JA, Fitzgerald J, Fitzgerald S, Kenny D, Kay EW, O'Kennedy R, et al. Diagnostic potential of zinc finger protein-specific autoantibodies and associated linear B-cell epitopes in colorectal cancer. PLoS One 2015;10:e0123469. DOI: https://doi.org/10.1371/journal.pone.0123469
Gaykalova DA, Vatapalli R, Wei Y, Tsai HL, Wang H, Zhang C, et al. Outlier analysis defines zinc finger gene family DNA methylation in tumors and saliva of head and neck cancer patients. PLoS One 2015;10:e0142148. DOI: https://doi.org/10.1371/journal.pone.0142148
Pan HX, Bai HS, Guo Y, Cheng ZY. Bioinformatic analysis of the prognostic value of ZNF860 in recurrence-free survival and its potential regulative network in gastric cancer. Eur Rev Med Pharmacol Sci 2019;23:162-70.
Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol 2016;22:823-32. DOI: https://doi.org/10.3748/wjg.v22.i2.823
Yang HY, Shen JX, Wang Y, Liu Y, Shen DY, Quan S. Tankyrase promotes aerobic glycolysis and proliferation of ovarian cancer through activation of Wnt/β-catenin signaling. Biomed Res Int 2019;2019:2686340. DOI: https://doi.org/10.1155/2019/2686340
Emons G, Spitzner M, Reineke S, Möller J, Auslander N, Kramer F, et al. Chemoradiotherapy resistance in colorectal cancer cells is mediated by Wnt/β-catenin signaling. Mol Cancer Res 2017;15:1481-90. DOI: https://doi.org/10.1158/1541-7786.MCR-17-0205
Bei C, Tan C, Zhu X, Wang Z, Tan S. Association between polymorphisms in CMTM family genes and hepatocellular carcinoma in Guangxi of China. DNA Cell Biol 2018;37:691-6. DOI: https://doi.org/10.1089/dna.2018.4274
Xu G, Dang C. CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. Cancer Cell Int 2017;17:113. DOI: https://doi.org/10.1186/s12935-017-0485-8
Li P, Liu K, Li L, Yang M, Gao W, Feng J, et al. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer. Int J Gynecol Cancer 2011;21:1248-55. DOI: https://doi.org/10.1097/IGC.0b013e3182259c31
Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget 2017;8:50209-20. DOI: https://doi.org/10.18632/oncotarget.16854
Byeon HK, Ku M, Yang J. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Exp Mol Med 2019;51:1-14. DOI: https://doi.org/10.1038/s12276-018-0202-2
Zhou X, Zhang W, Yao Q, Zhang H, Dong G, Zhang M, et al. Exosome production and its regulation of EGFR during wound healing in renal tubular cells. Am J Physiol Renal Physiol 2017;312:F963-70. DOI: https://doi.org/10.1152/ajprenal.00078.2017
Venkataraman T, Coleman CM, Frieman MB. Overactive epidermal growth factor receptor signaling leads to increased fibrosis after Severe Acute Respiratory Syndrome Coronavirus infection. J Virol 2017;91:e00182-17. DOI: https://doi.org/10.1128/JVI.00182-17
Shi YY, Liu HF, Min M, Wang W, Li J, He CY, et al. Correlation analysis of mast cells and EGFR with endoscopic application of tissue glue for treatment of peptic ulcer healing. Eur Rev Med Pharmacol Sci 2017;21:861-6.

How to Cite

Chen, Z. ., Cui, N. ., Zhao, J.- sen ., Wu, J.- fei ., Ma, F. ., Li, C. ., & Liu, X.- yi. (2021). Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances. European Journal of Histochemistry, 65(1). https://doi.org/10.4081/ejh.2021.3173